← Leaderboards
Michael J. Jurczak
University Of Pittsburgh At Pittsburgh
$3,728,877
Attributed
$5,117,459
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $767K · FY2013–25$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,117,459 · 6
By mechanism
R01$4,469,198 · 3
K01$441,339 · 1
R03$155,479 · 1
T35$51,443 · 1
Top collaborators
- Yuan Liu5 shared
- Jonathan K. Alder1 shared
- Donald B Defranco1 shared
- Thomas R. Kleyman1 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Andrea Beth Goldschmidt$7,108,940
- Donald B Defranco$10,683,038
- Yuan Liu$4,548,206
- Jaideep Behari$4,660,334
- Nicholas Khoo$680,523
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingPathway InteractionsObesitySignal TransductionLiverCellsMetabolicPathogenesisDesignResearch DesignInsulin ResistanceHepaticNon-Insulin-Dependent Diabetes MellitusProteinsDietMolecularUbiquitinUbiquitin-Protein LigaseProductionSignal PathwayMitochondriaAffectGeneticMetabolic Diseases
Grant awards (18)
Novel aspects of Gdf15 biology and function$659,199
R01 · FY2025 · DK · contact PI
Training in Renal, GI, Endocrine and Epithelial Biology$51,443
T35 · FY2024 · DK
Role of Fbxo48-mediated AMPK proteostasis in the pathogenesis and treatment of NAFLD$408,615
R01 · FY2023 · DK · contact PI
Role of Fbxo48-mediated AMPK proteostasis in the pathogenesis and treatment of NAFLD$408,615
R01 · FY2022 · DK · contact PI
Obesity-associated Mitophagy Resistance$352,125
R01 · FY2022 · DK · contact PI
Role of Fbxo48-mediated AMPK proteostasis in the pathogenesis and treatment of NAFLD$414,914
R01 · FY2021 · DK · contact PI
Obesity-associated Mitophagy Resistance$352,125
R01 · FY2021 · DK · contact PI
Role of Fbxo48-mediated AMPK proteostasis in the pathogenesis and treatment of NAFLD$408,615
R01 · FY2020 · DK · contact PI
Obesity-associated Mitophagy Resistance$352,125
R01 · FY2020 · DK · contact PI
Role of Fbxo48-mediated AMPK proteostasis in the pathogenesis and treatment of NAFLD$408,615
R01 · FY2019 · DK · contact PI
Obesity-associated Mitophagy Resistance$352,125
R01 · FY2019 · DK · contact PI
Obesity-associated Mitophagy Resistance$352,125
R01 · FY2018 · DK · contact PI
Park2,impaired lipid absorption and protection from diet-induced obesity$78,041
R03 · FY2018 · DK · contact PI
Park2,impaired lipid absorption and protection from diet-induced obesity$77,438
R03 · FY2017 · DK · contact PI
Parkin's role in hepatic mitochondrial turnover, steatosis and insulin resistance$117,939
K01 · FY2015 · DK · contact PI
Parkin's role in hepatic mitochondrial turnover, steatosis and insulin resistance$29,174
K01 · FY2015 · DK · contact PI
Parkin's role in hepatic mitochondrial turnover, steatosis and insulin resistance$147,113
K01 · FY2014 · DK · contact PI
Parkin's role in hepatic mitochondrial turnover, steatosis and insulin resistance$147,113
K01 · FY2013 · DK · contact PI